General expert consensus on the application of network pharmacology in the research and development of new traditional Chinese medicine drugs.
10.1016/S1875-5364(25)60802-8
- Author:
Shao LI
1
;
Wei XIAO
2
,
3
Author Information
1. Institute of TCM-X/MOE Key Laboratory of Bioinformatics, Bioinformatics Division, BNRist/Department of Automation, Tsinghua University, Beijing 100084, China. Electronic address: shaoli@mail.tsinghua.edu.cn.
2. State Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture, Jiangsu Kanion Pharmaceutical Co., Ltd., Lianyungang 222047, China. Electronic address: kanionlunwen@
3. com.
- Publication Type:Consensus Development Conference
- Keywords:
Expert consensus;
Network pharmacology;
Research and development of new traditional Chinese medicine drugs
- MeSH:
Humans;
Consensus;
Drug Development/standards*;
Drugs, Chinese Herbal/chemistry*;
Medicine, Chinese Traditional;
Network Pharmacology/standards*;
Guidelines as Topic
- From:
Chinese Journal of Natural Medicines (English Ed.)
2025;23(2):129-142
- CountryChina
- Language:English
-
Abstract:
The research and development of new traditional Chinese medicine (TCM) drugs have progressively established a novel system founded on the integration of TCM theory, human experience, and clinical trials (termed the "Three Combinations"). However, considering TCM's distinctive features of "syndrome differentiation and treatment" and "multicomponent formulations and complex mechanisms", current TCM drug development faces challenges such as insufficient understanding of the material basis and the overall mechanism of action and an incomplete evidence chain system. Moreover, significant obstacles persist in gathering human experience data, evaluating clinical efficacy, and controlling the quality of active ingredients, which impede the innovation process in TCM drug development. Network pharmacology, centered on the "network targets" theory, transcends the limitations of the conventional "single target" reductionist research model. It emphasizes the comprehensive effects of disease or syndrome biological networks as targets to elucidate the overall regulatory mechanism of TCM prescriptions. This approach aligns with the holistic perspective of TCM, offering a novel method consistent with TCM's holistic view for investigating the complex mechanisms of TCM and developing new TCM drugs. It is internationally recognized as a "next-generation drug research model". To advance the research of new tools, methods, and standards for TCM evaluation and to overcome fundamental, critical, and cutting-edge technical challenges in TCM regulation, this consensus aims to explore the characteristics, progress, challenges, applicable pathways, and specific applications of network pharmacology as a new theory, method, and tool in TCM drug development. The goal is to enhance the quality of TCM drug research and development and accelerate the efficiency of developing new TCM products.
